In 2005, the Food and Drug Administration (FDA) approved exenatide (Byetta), the first glucagon-like peptide-1 ( GLP-1 ) receptor agonist, which was designed to help lower blood glucose levels (blood sugar)in people with type 2 diabetes
When taken as a weekly injection, it helps regulate blood sugar levels, slow down the rate at which food is digested, and increase fullness after you eat
If you have concerns about discomfort, we can discuss options to help make the experience more comfortable
For example, a history of heart disease may point toward semaglutide, since certain formulations carry cardiovascular risk-reduction approval
Three gummies, 3.75g delivered, done
GoodpasterBDelanyJOttoAKullerLVockleyJSouth-PaulJet alEffects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: A randomized trial